Harr Steve 4

What Happened

• Steve Harr, President, Chief Executive Officer and Director of Sana Biotechnology (SANA), had restricted stock units convert into common shares (reported as exercise/conversion of a derivative). He acquired 41,666 shares on 2026-03-06 and 50,000 shares on 2026-03-07 (total 91,666) at $0.00 per share.
• To cover tax withholding, 11,526 shares were surrendered on 2026-03-09 at $3.13/share and 12,819 shares were surrendered on 2026-03-09 at $3.10/share, generating cash proceeds of about $36,076 and $39,739 respectively (total ≈ $75,815). Net shares retained from these conversions = 91,666 − 24,345 = 67,321 shares.

Key Details

• Transaction dates: conversions on 2026-03-06 and 2026-03-07; tax withholding/surrender on 2026-03-09. Filing date: 2026-03-10 (appears timely under the SEC two-business-day rule).
• Transaction codes: M = exercise/conversion of derivative (here, RSUs converting to common stock); F = payment of exercise price or tax liability (shares withheld/surrendered).
• Shares surrendered for tax withholding: 24,345 shares for ~$75,815 total.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — certain shares are held in trusts for immediate-family beneficiaries; F2 — each RSU equals one contingent share; F3/F4 — describe vesting schedules (portions vested on March 6/7, 2026 with remaining installments in later years).

Context

• This is a routine vesting + tax-withholding transaction (not an open-market sale). Converting RSUs at $0 reflects vesting, and surrendering shares to cover taxes is a common cashless withholding method that does not necessarily indicate a change in insider sentiment.